ES2196026T3 - Uso de ndv en la fabricacion de un medicamento para tratar el cancer. - Google Patents
Uso de ndv en la fabricacion de un medicamento para tratar el cancer.Info
- Publication number
- ES2196026T3 ES2196026T3 ES94916604T ES94916604T ES2196026T3 ES 2196026 T3 ES2196026 T3 ES 2196026T3 ES 94916604 T ES94916604 T ES 94916604T ES 94916604 T ES94916604 T ES 94916604T ES 2196026 T3 ES2196026 T3 ES 2196026T3
- Authority
- ES
- Spain
- Prior art keywords
- ndv
- manufacture
- treat cancer
- medicinal product
- mammal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 241000711404 Avian avulavirus 1 Species 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000973 chemotherapeutic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229940125721 immunosuppressive agent Drugs 0.000 abstract 1
- 239000003018 immunosuppressive agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A61K39/17—Newcastle disease virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0331—Animal model for proliferative diseases
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
- C12N2760/18132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
LA INVENCION PROPORCIONA UN METODO DE TRATAMIENTO DE CANCER EN UN MAMIFERO QUE COMPRENDE LA ADMINISTRACION AL MAMIFERO DE UNA CANTIDAD EFECTIVA DE VIRUS, PARTICULARMENTE VIRUS DE LA ENFERMEDAD DE NEWCASTLE O OTROS PARAMIXOVIRUS. LA INVENCION ADEMAS PROPORCIONA UN METODO DE TRATAMIENTO DE CANCER EN UN MAMIFERO QUE COMPRENDE LA ADMINISTRACION DE TALES VIRUS AL MAMIFERO EN COMBINACION CON OTRO AGENTE COMO UN COMPUESTO QUIMIOTERAPEUTICO, INMUNOADYUVANTE, CITOQUINA O AGENTE INMUNOSUPRESOR. LA INVENCION PROPORCIONA ADEMAS UN METODO DE DETECCION DE CELULAS CANCERIGENAS EN UN MAMIFERO UTILIZANDO PARAMIXOVIRUS COMO UN AGENTE DE PRESENTACION Y COMO UN INDICADOR DEL CRECIMIENTO DE CELULAS CANCERIGENAS EN EL MAMIFERO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5551993A | 1993-04-30 | 1993-04-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2196026T3 true ES2196026T3 (es) | 2003-12-16 |
Family
ID=21998395
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES94916604T Expired - Lifetime ES2196026T3 (es) | 1993-04-30 | 1994-04-29 | Uso de ndv en la fabricacion de un medicamento para tratar el cancer. |
ES02026340T Expired - Lifetime ES2310580T3 (es) | 1993-04-30 | 1994-04-29 | Composiciones purificadas del virus de la enfermedad de newcastle. |
ES04017349T Expired - Lifetime ES2315595T3 (es) | 1993-04-30 | 1994-04-29 | Composiciones para tratar cancer con uso de virus. |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES02026340T Expired - Lifetime ES2310580T3 (es) | 1993-04-30 | 1994-04-29 | Composiciones purificadas del virus de la enfermedad de newcastle. |
ES04017349T Expired - Lifetime ES2315595T3 (es) | 1993-04-30 | 1994-04-29 | Composiciones para tratar cancer con uso de virus. |
Country Status (12)
Country | Link |
---|---|
US (2) | US7056689B1 (es) |
EP (4) | EP1486211B1 (es) |
JP (3) | JP4338781B2 (es) |
AT (3) | ATE236271T1 (es) |
AU (1) | AU699487B2 (es) |
CA (1) | CA2161671A1 (es) |
DE (3) | DE69435155D1 (es) |
DK (3) | DK1314431T3 (es) |
ES (3) | ES2196026T3 (es) |
HK (1) | HK1052871A1 (es) |
PT (3) | PT1314431E (es) |
WO (1) | WO1994025627A1 (es) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1314431T3 (da) * | 1993-04-30 | 2008-11-10 | Wellstat Biologics Corp | Oprensede sammensætninger af Newcastle disease virus |
US7780962B2 (en) | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
US20030044384A1 (en) | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
US7470426B1 (en) | 1997-10-09 | 2008-12-30 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
NZ518945A (en) * | 1997-10-09 | 2007-03-30 | Wellstat Biologics Corp | Treatment of neoplasms with viruses |
FR2788099B1 (fr) | 1999-01-06 | 2001-02-09 | Vallourec Mannesmann Oil & Gas | Assemblage filete de deux tubes metalliques a couple eleve de vissage |
AU2005201079C1 (en) * | 1999-04-15 | 2008-11-06 | Wellstat Biologics Corporation | Treatment of neoplasms with viruses |
EP1390046A4 (en) * | 1999-04-15 | 2005-04-20 | Wellstat Biologics Corp | TREATMENT OF NEOPLASMS WITH VIRUSES |
US8147822B1 (en) | 1999-09-17 | 2012-04-03 | Wellstat Biologics Corporation | Oncolytic virus |
AUPQ425699A0 (en) | 1999-11-25 | 1999-12-23 | University Of Newcastle Research Associates Limited, The | A method of treating a malignancy in a subject and a pharmaceutical composition for use in same |
US8491884B2 (en) | 2000-05-03 | 2013-07-23 | Oncolytics Biotech Inc. | Virus clearance of neoplastic cells from mixed cellular compositions |
AR028039A1 (es) | 2000-05-03 | 2003-04-23 | Oncolytics Biotech Inc | Remocion de reovirus de celulas neoplasticas intermediadas por ras a partir de composiciones celulares mixtas |
US7306902B2 (en) | 2002-06-28 | 2007-12-11 | Oncolyties Biotech Inc. | Oncolytic viruses as phenotyping agents for neoplasms |
US20020037543A1 (en) | 2000-06-26 | 2002-03-28 | Atkins Harold L. | Purging of cells using viruses |
AR035227A1 (es) | 2001-02-20 | 2004-05-05 | Oncolytics Biotech Inc | Uso de un agente quimioterapeutico para la manufactura de un medicamento para la sensibilizacion de celulas neoplasicas resistentes a agentes quimioterapeuticos con reovirus |
NZ527687A (en) | 2001-05-11 | 2005-10-28 | Wellstat Biolog Corp Formerly | Preferential binding of an oncolytic virus such as Newcastle Disease Virus (NDV) to leukocytes compared with erythrocytes used as a therapy for cancer |
IL145397A0 (en) * | 2001-09-12 | 2002-06-30 | Yissum Res Dev Co | Compositions and methods for treatment of cancer |
US7615209B2 (en) * | 2001-09-12 | 2009-11-10 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Compositions of NDV and methods of use thereof for treatment of cancer |
CA2374388C (en) | 2002-02-28 | 2005-07-12 | Matthew C. Coffey | The use of ribozymes in the detection of adventitious agents |
US20040005546A1 (en) | 2002-02-28 | 2004-01-08 | Oncolytics Biotech Inc. | Use of ribozymes in the detection of adventitious agents |
CA2489523A1 (en) * | 2002-06-21 | 2003-12-31 | Wellstat Biologics Corporation | Administration of therapeutic viruses |
CA2502890A1 (en) * | 2002-11-05 | 2004-05-27 | Wellstat Biologics Corporation | Treating carcinoid neoplasms with therapeutic viruses |
AU2002953436A0 (en) | 2002-12-18 | 2003-01-09 | The University Of Newcastle Research Associates Limited | A method of treating a malignancy in a subject via direct picornaviral-mediated oncolysis |
KR20050115930A (ko) * | 2003-03-24 | 2005-12-08 | 웰스테트 바이올로직스 코포레이션 | 항-암 바이러스의 탈감작화 방법 |
WO2005042737A1 (ja) * | 2003-11-04 | 2005-05-12 | Dnavec Research Inc. | 遺伝子導入された樹状細胞の製造方法 |
WO2005051433A1 (en) * | 2003-11-25 | 2005-06-09 | United Cancer Research Institute | Method for treating human tumor cells with a newcastle disease virus strain and a chemotherapeutic agent |
CN1946421B (zh) | 2004-04-27 | 2013-07-17 | 威尔斯达特生物制剂公司 | 使用病毒和喜树碱进行的癌症治疗 |
US20080031855A1 (en) | 2004-06-24 | 2008-02-07 | Dnavec Research Inc. | Anticancer Agent Containing Minus-Strand Rna Virus |
RU2435586C2 (ru) * | 2005-07-14 | 2011-12-10 | Веллстат Байолоджикс Корпорейшн | Лечение рака с применением вирусов, фторпиримидинов и камптотецинов |
PT2251034T (pt) | 2005-12-02 | 2018-05-22 | Icahn School Med Mount Sinai | Vírus da doença de newcastle quiméricos que apresentam proteínas de superfície não nativas e suas utilizações |
US20090175826A1 (en) * | 2006-06-05 | 2009-07-09 | Elankumaran Subbiah | Genetically-engineered newcastle disease virus as an oncolytic agent, and methods of using same |
WO2008144067A1 (en) * | 2007-05-21 | 2008-11-27 | Board Of Regents, University Of Texas System | Methods and compositions for treatment of cancer using oncolytic rsv activity |
JP5547640B2 (ja) * | 2008-09-16 | 2014-07-16 | ジェノミディア株式会社 | 前立腺癌の治療・予防剤 |
WO2010091262A1 (en) | 2009-02-05 | 2010-08-12 | Mount Sinai School Of Medicine Of New York University | Chimeric newcastle disease viruses and uses thereof |
EP2327764B1 (en) | 2009-11-30 | 2011-12-28 | United Cancer Research Institute | New clone of Newcastle disease virus, its manufacture and its application in the medical treatment of cancer |
BR112015021414B1 (pt) | 2013-03-14 | 2020-11-10 | Icahn School Of Medicine At Mount Sinai | vírus da doença newcastle e seus usos |
WO2015127501A1 (en) | 2014-02-27 | 2015-09-03 | Viralytics Limited | Combination method for treatment of cancer |
KR20240073085A (ko) | 2017-05-10 | 2024-05-24 | 파마 싱크, 엘엘씨 | 암 치료용 보체 불활성화 내성의 외피 바이러스 |
Family Cites Families (60)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3577525A (en) | 1964-07-01 | 1971-05-04 | Cornell Res Foundation Inc | Adenovirus vaccine against canine hepatitis |
NL7111160A (es) | 1971-03-09 | 1972-09-12 | ||
ZA754725B (en) | 1974-08-01 | 1976-06-30 | H Stickl | Preparation for the treatment of infectious diseases, method for the manufacture thereof, and its use |
JPS5173117A (en) * | 1974-12-19 | 1976-06-24 | Handai Biseibutsubyo Kenkyukai | Ganryohozaino seiho |
US4108983A (en) | 1976-06-01 | 1978-08-22 | The Wistar Institute | Viral oncolysate vaccine for stimulating the immune mechanism of mammals to species-specific tumors |
US4126671A (en) | 1976-08-17 | 1978-11-21 | Pitman-Moore, Inc. | Method for detecting bovine leukemia viral infection |
US4379839A (en) | 1977-05-23 | 1983-04-12 | The Trustees Of Columbia University In The City Of New York | Method for detecting cancer |
IT1117218B (it) | 1979-05-18 | 1986-02-17 | Depa Sas | Procedimento per la produzione di un prodotto per la diagnosi dei tumori delle parti molli o carcinomi e prodotto ottenuto |
US4282315A (en) | 1979-09-13 | 1981-08-04 | Corning Glass Works | Preparation of enriched whole virus radioligand |
US4334016A (en) | 1980-06-19 | 1982-06-08 | The Wistar Institute Of Anatomy And Biology | Human osteogenic sarcoma cell line and use thereof for immunofluorescent antibody test |
US4405712A (en) | 1981-07-01 | 1983-09-20 | The United States Of America As Represented By The Department Of Health And Human Services | LTR-Vectors |
US4465769A (en) | 1981-12-11 | 1984-08-14 | The United States Of America As Represented By The Department Of Health And Human Services | Non-transformed thymidine kinaseless cell line and its use for testing tumorigenic potential of genes |
JPS58116422A (ja) | 1981-12-28 | 1983-07-11 | Green Cross Corp:The | 抗腫瘍剤 |
US4582787A (en) | 1982-12-30 | 1986-04-15 | Frankel Jack W | Method of testing a patient for a predisposition to lung cancer, certain other cancers, neurofibromatosis and certain other hereditary disorders |
US4571385A (en) | 1983-06-27 | 1986-02-18 | The United States Of America As Represented By The Department Of Health And Human Services | Genetic reassortment of rotaviruses for production of vaccines and vaccine precursors |
US4748109A (en) | 1983-07-01 | 1988-05-31 | Baird Phillip J | Assay method and reagent to determine antibodies to papillomavirus virions |
US4647773A (en) | 1984-04-23 | 1987-03-03 | The United States Of America As Represented By The Department Of Health And Human Services | Method of continuous production of retroviruses (HTLV-III) from patients with AIDS and pre-AIDS |
JPS60249058A (ja) | 1984-05-25 | 1985-12-09 | Eisai Co Ltd | Atlウイルス抗体の測定方法および試薬 |
HU197846B (en) | 1984-07-02 | 1989-06-28 | Laszlo Csatary | Process for producing therapeutic composition suitable for treating virus infections |
US5075213A (en) | 1984-07-27 | 1991-12-24 | City Of Hope | Method for detection and prevention of human cytomegalovirus infection |
HU197517B (en) | 1984-07-30 | 1989-04-28 | Laszlo Csatary | Process for production of terapeutical composition applicable against virus infection |
FR2593828B2 (fr) | 1986-01-31 | 1990-05-04 | Pasteur Institut | Sonde a papillomavirus et procede de diagnostic in-vitro d'infections a papillomavirus |
US4735895A (en) | 1984-12-28 | 1988-04-05 | Oncotech, Inc. | Cancer susceptibility test |
GB8500918D0 (en) | 1985-01-15 | 1985-02-20 | Cancer Res Inst | Viral isolates |
US4786590A (en) | 1985-01-15 | 1988-11-22 | California Institute Of Technology | Diagnostic and therapeutic aspects of receptor-mediated leukemogenesis |
US4970071A (en) | 1985-01-18 | 1990-11-13 | Mcmichael John | Immunotherapeutic methods and compositions employing antigens characteristic of non human malignant neoplasms |
US4777127A (en) | 1985-09-30 | 1988-10-11 | Labsystems Oy | Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus |
JPS63501923A (ja) | 1985-12-05 | 1988-08-04 | フレツド ハツチンソン キヤンサ− リサ−チ センタ− | レトロウイルス疾病状態の治療のためのアンチセンスrna |
AU602875B2 (en) | 1985-12-18 | 1990-11-01 | British Technology Group Limited | Newcastle disease virus gene clones |
US4839288A (en) | 1986-01-22 | 1989-06-13 | Institut Pasteur | Retrovirus capable of causing AIDS, antigens obtained from this retrovirus and corresponding antibodies and their application for diagnostic purposes |
US4861719A (en) | 1986-04-25 | 1989-08-29 | Fred Hutchinson Cancer Research Center | DNA constructs for retrovirus packaging cell lines |
US4861720A (en) | 1986-07-03 | 1989-08-29 | Regents Of The University Of California | Oncornavirus vaccines and feline alpha-type interferon |
NZ224567A (en) * | 1987-05-19 | 1990-08-28 | Yissum Res Dev Co | Vaccine against newcastle disease virus comprising a live immunogenic lentogenic or mesogenic strain of newcastle disease virus in combination with a liquid containing a mineral or vegetable oil |
US4849334A (en) | 1987-06-09 | 1989-07-18 | Life Technologies, Inc. | Human papillomavirus 43 nucleic acid hybridization probes and methods for employing the same |
US4908306A (en) | 1987-06-12 | 1990-03-13 | Life Technologies, Inc. | Human papillomavirus 56 nucleic acid hybridization probes and methods for employing the same |
DE3722968A1 (de) | 1987-07-11 | 1989-01-19 | Behringwerke Ag | Humaner papillomvirus typ 41, seine dna und die dafuer kodierenden proteine |
CA1341439C (en) | 1987-08-26 | 2003-09-23 | Niels C. Pedersen | Feline t-lymphotropic lentivirus |
ATE208813T1 (de) | 1988-02-16 | 2001-11-15 | Greatbatch Gen Aid Ltd | Modifizierte zellen mit resistenz gegen retroviralinfektionen |
DE3806565A1 (de) | 1988-03-01 | 1989-09-14 | Deutsches Krebsforsch | Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen |
US5077198A (en) | 1988-04-14 | 1991-12-31 | Eastman Kodak Company | Diagnostic kit and method for rapid detection of antibodies |
US5215745A (en) | 1988-04-27 | 1993-06-01 | United Cancer Research Institute | Method for treating viral diseases with attenuated virus |
US5124148A (en) | 1988-04-27 | 1992-06-23 | United Cancer Research Institute | Method for treating viral diseases with attenuated virus |
FR2632956B2 (fr) | 1988-05-13 | 1991-07-12 | Pasteur Institut | Sondes a papillomavirus hpv49, hpv50, hpv54, hpv55; produits genetiquement et immunologiquement lies a ce papillomavirus hpv49, hpv50, hpv54, hpv55; procede de diagnostic in vitro d'infections a papillomavirus et d'immunisation in vivo contre ces papillomavirus |
US5192539A (en) | 1988-07-21 | 1993-03-09 | Akzo N.V. | Infectious bursal disease virus production in continuous cell lines |
US5057314A (en) | 1988-09-30 | 1991-10-15 | Whitfill Craig E | Low molecular weight antiviral factors |
FR2639225B1 (fr) | 1988-11-21 | 1993-05-21 | Centre Nat Rech Scient | Compositions pharmaceutiques pour la neuroprotection contenant des arylcyclohexylamines |
US5045447A (en) | 1989-03-15 | 1991-09-03 | Minson Anthony C | Method of producing antibodies to HPV |
US5169753A (en) | 1989-06-05 | 1992-12-08 | Genelabs Incorporated | Method and kit for detecting human retrovirus |
FR2656627B1 (fr) | 1989-12-28 | 1992-04-17 | Pasteur Institut | Sonde a papillomavirus (hvpv63), notamment pour le diagnostic in vitro d'infections a papillomavirus, pouvant s'accompagner de neoplasies genitales, et produits genetiquement et immunologiquement lies a ce papillomavirus. |
CN1054192A (zh) * | 1990-02-26 | 1991-09-04 | 张炳团 | 人体内诱导干扰素的制造方法 |
US6399569B1 (en) * | 1991-03-11 | 2002-06-04 | Curis, Inc. | Morphogen treatments for limiting proliferation of epithelial cells |
US5252479A (en) | 1991-11-08 | 1993-10-12 | Research Corporation Technologies, Inc. | Safe vector for gene therapy |
US5195539A (en) * | 1992-03-23 | 1993-03-23 | Minnesota Mining And Manufacturing Company | Earplug compression device |
DK0713397T3 (da) | 1992-03-24 | 2003-03-31 | United Cancer Res Inst | Vaccine indeholdende levende virus |
AU682854B2 (en) | 1993-02-16 | 1997-10-23 | Onyx Pharmaceuticals | Cytopathic viruses for therapy and prophylaxis of neoplasia |
ATE208421T1 (de) | 1993-03-16 | 2001-11-15 | Hoegen Paul Von | Stimulierung der immunantwort durch virales protein |
DK1314431T3 (da) * | 1993-04-30 | 2008-11-10 | Wellstat Biologics Corp | Oprensede sammensætninger af Newcastle disease virus |
US7780962B2 (en) * | 1997-10-09 | 2010-08-24 | Wellstat Biologics Corporation | Treatment of neoplasms with RNA viruses |
US20030044384A1 (en) * | 1997-10-09 | 2003-03-06 | Pro-Virus, Inc. | Treatment of neoplasms with viruses |
CA2502890A1 (en) * | 2002-11-05 | 2004-05-27 | Wellstat Biologics Corporation | Treating carcinoid neoplasms with therapeutic viruses |
-
1994
- 1994-04-29 DK DK02026340T patent/DK1314431T3/da active
- 1994-04-29 AU AU68213/94A patent/AU699487B2/en not_active Ceased
- 1994-04-29 DE DE69435155T patent/DE69435155D1/de not_active Expired - Lifetime
- 1994-04-29 ES ES94916604T patent/ES2196026T3/es not_active Expired - Lifetime
- 1994-04-29 DK DK04017349T patent/DK1486211T3/da active
- 1994-04-29 ES ES02026340T patent/ES2310580T3/es not_active Expired - Lifetime
- 1994-04-29 WO PCT/US1994/004732 patent/WO1994025627A1/en active IP Right Grant
- 1994-04-29 DK DK94916604T patent/DK0696326T5/da active
- 1994-04-29 PT PT02026340T patent/PT1314431E/pt unknown
- 1994-04-29 AT AT94916604T patent/ATE236271T1/de not_active IP Right Cessation
- 1994-04-29 DE DE69432409T patent/DE69432409T2/de not_active Expired - Lifetime
- 1994-04-29 EP EP04017349A patent/EP1486211B1/en not_active Expired - Lifetime
- 1994-04-29 AT AT04017349T patent/ATE411809T1/de not_active IP Right Cessation
- 1994-04-29 DE DE69435118T patent/DE69435118D1/de not_active Expired - Lifetime
- 1994-04-29 EP EP02026340A patent/EP1314431B1/en not_active Expired - Lifetime
- 1994-04-29 EP EP94916604A patent/EP0696326B1/en not_active Expired - Lifetime
- 1994-04-29 ES ES04017349T patent/ES2315595T3/es not_active Expired - Lifetime
- 1994-04-29 AT AT02026340T patent/ATE401092T1/de not_active IP Right Cessation
- 1994-04-29 PT PT04017349T patent/PT1486211E/pt unknown
- 1994-04-29 JP JP52456394A patent/JP4338781B2/ja not_active Expired - Fee Related
- 1994-04-29 EP EP08166836A patent/EP2009119A1/en not_active Withdrawn
- 1994-04-29 PT PT94916604T patent/PT696326E/pt unknown
- 1994-04-29 CA CA002161671A patent/CA2161671A1/en not_active Abandoned
- 1994-06-16 US US08/260,536 patent/US7056689B1/en not_active Expired - Lifetime
-
2003
- 2003-07-12 HK HK03105047.9A patent/HK1052871A1/zh unknown
-
2005
- 2005-03-24 JP JP2005087342A patent/JP2005187484A/ja not_active Withdrawn
-
2006
- 2006-05-26 US US11/441,201 patent/US7736640B2/en not_active Expired - Fee Related
-
2009
- 2009-03-26 JP JP2009077773A patent/JP2009149689A/ja not_active Withdrawn
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2196026T3 (es) | Uso de ndv en la fabricacion de un medicamento para tratar el cancer. | |
FI950697A (fi) | IL-4:n ja/tai IL-10:n uudet käytöt ja vasta-aineet niitä vastaan | |
MX9305146A (es) | Conjugado de interferon, procedimiento para su preracion y composicion farmaceutica que lo contienen. | |
ES2065701T3 (es) | Furoato de mometasona monohidrato, procedimiento para fabricar el mismo y composiciones farmaceuticas. | |
ATE225341T1 (de) | In 6-position durch thio substituierte paclitaxele | |
FI943749A0 (fi) | Taksaanijohdannaisten fosfono-oksimetyylieetterit | |
DK0392300T3 (da) | Anvendelse af lægemidler, der indeholder mindst et cytokin, til systemisk behandling af præneoplastiske læsioner | |
DE3587434D1 (de) | Antivirale pharmazeutische zusammensetzungen und ihrer verwendung. | |
DE69811062D1 (de) | Polyaromatische antivirale zusammensetzungen | |
AR003119A1 (es) | Composicion farmaceutica para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres que comprenden una mezcla de un n- clorofenilcarbamato o un n- clorofeniltiocarbamato y un n- fosfonoglicina y uso de dicha composicion farmaceutica para la manufactura de un medicamento para tratar infecciones virosicas o inhibir el crecimiento de tumores o canceres | |
ATE265535T1 (de) | Pharmazeutische zusammensetzung gegen durch papillomaviren verursachte tumoren und infektionen | |
AR002987A1 (es) | Composicion farmaceutica para el tratamiento de infecciones virales ocanceres o tumores, composicion de dosis unitaria que la comprende y uso para dicho tratamiento | |
BR9407257A (pt) | Composto do tipo bis-naftalimida composição farmacêutica processo para tratamento de um tumor em mamifero uso do composto do tipo bis-naftalimida e processo para a preparação compostos do tipo bis-naftalimida | |
EA200400670A1 (ru) | Фармацевтические композиции, содержащие 3,4-пропинопергидропурины, и их применение для блокирования нейронной передачи | |
BR9202709A (pt) | Composicao,processo para aperfeicoar as propriedades de uso de lubrificantes e compostos | |
BR9106272A (pt) | Composicoes farmaceuticas contendo ipriflavona,processo para sua preparacao e uso terapeutico relativo | |
BR9106596A (pt) | Processo para o tratamento ou profilaxia de uma infeccao associada com retrovirus,uso,composicao farmaceutica para o tratamento ou profilaxia de uma infeccao associada com retrovirus,e,composto | |
BR9812002A (pt) | Compostos com efeito antiprimeiro-passe | |
NO913502D0 (no) | Kompositt for anvendelse som hoeyenergi-sprengstoff eller drivmiddel. | |
ATE47863T1 (de) | Makrolide derivate. | |
MX9401370A (es) | Terapia antiviral. | |
ECSP941089A (es) | Agentes arilantes | |
ES1006093Y (es) | Juego de composicion para la formacion de cuadros. | |
ES2086395T3 (es) | Fosfolipidos para el tratamiento de esclerosis multiple. | |
MX9203089A (es) | Composicion para el tratamiento de esquisofrenia. |